Search clinical trials for: ABBV-599

Total 269 results

AbbVie

Active, not recruiting

A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused ABBV-383 of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan

Relapsed/Refractory Multiple Myeloma

Japan
AbbVie

Available

Expanded Access to ABBV-400

Non-Small Cell Lung Cancer
VA Office of Research and Development

Completed

Transfusion Trigger After Operations in High Cardiac Risk Patients (TOP)

Myocardial Infarction | Acute Renal Failure | Coronary Revascularization

United States
AbbVie
Infinity Pharmaceuticals, Inc.

Completed

Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma

Lymphoma

Japan
AbbVie

Recruiting

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

Advanced Solid Tumors Cancer

United States, Australia, Israel, Japan, Korea, Republic of, Puerto Rico, Spain, Taiwan, Canada, France, Belgium
AbbVie

Completed

A Study to Assess Adverse Events and How Single and Multiple Ascending Doses of ABBV-903 Move Through the Body in Healthy Adults

Healthy Volunteer

United States
AbbVie

No longer available

Expanded Access to Risankizumab

Crohn's Disease | Ulcerative Colitis (UC)
Calico Life Sciences LLC
AbbVie

Completed

A Phase 1 Study Assessing the Effect of Food on the Pharmacokinetics of ABBV- CLS-7262

Healthy

United States
AbbVie

Recruiting

A Study in Healthy Adult Participants to Assess the Pharmacokinetics, Immunogenicity, Safety, and Tolerability of a Ravagalimab Subcutaneous Formulation in a Pre-Filled Syringe

Healthy Volunteers

United States
AbbVie
Gedeon Richter Plc.

Active, not recruiting

Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants

Healthy Participants | Generalized Anxiety Disorder (GAD)

United States
AbbVie

Completed

A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) (LIMMITLESS)

Psoriasis

United States, Australia, Austria, Belgium, Canada, Czechia, Finland, France, Germany, Japan, Korea, Republic of, Mexico, Poland, Portugal, Spain, Sweden, Taiwan
AbbVie

Completed

A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis

Dermatitis

United States, Australia, Canada, Japan, Puerto Rico
AbbVie

Completed

A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (NCT02719171)

Psoriatic Arthritis
AbbVie

Not yet recruiting

A Study to Assess the Relative Bioavailability of Three Immediate-Release Tablet Formulations of ABBV-903 in Healthy Adult Volunteers

Healthy Volunteers
AbbVie

Recruiting

Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States, Israel, Japan, Australia, Korea, Republic of
AbbVie

Recruiting

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

Hematologic Cancer

United States, Israel, Japan
TeneoOne Inc.

Recruiting

A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Israel, United States, Canada, Spain, France, Denmark, United Kingdom
AbbVie

Recruiting

Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

Diffuse Large B-Cell Lymphoma | Non-Hodgkin's Lymphoma | Chronic Lymphocytic Leukemia | B Cell Malignancies

United States, Israel, Australia, France, United Kingdom, Belgium, Spain
AbbVie

Recruiting

Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Belgium, France, Poland
AbbVie

Recruiting

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Chronic Lymphocytic Leukemia

United States, Australia, Canada, Israel
AbbVie

Available

Expanded Access to ABBV-787

Acute Myeloid Leukemia
AbbVie

Completed

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease

Parkinson's Disease (PD)

United States
AbbVie

Completed

A Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Participants With Solid Tumors

Advanced Solid Tumors Cancer

Japan
AbbVie

Terminated

A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)

Advanced Solid Tumors Cancer

United States, Australia, Denmark, Spain
AbbVie

Available

Expanded Access to Telisotuzumab Vedotin

Non-Small Cell Lung Cancer (NSCLC)

Australia, Hong Kong, Israel, United States, Germany
AbbVie

Terminated

A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis

Psoriasis

United States, Canada, Japan
AbbVie
Genmab

No longer available

Expanded Access to Epcoritamab

Lymphoma
AbbVie

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.

Crohn's Disease

United States, Canada, Israel, Taiwan, Japan, Korea, Republic of, United Kingdom
Calico Life Sciences LLC
AbbVie

Recruiting

An Open-Label Exploratory Study of ABBV-CLS-7262 Subjects With Vanishing White Matter Disease

Vanishing White Matter Disease

United States, Netherlands
Memorial Sloan Kettering Cancer Center

Active, not recruiting

A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors

Pituitary Adenoma | Brain Cancer

United States
AbbVie

Completed

Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar Pustulosis Area and Severity Index [PPPASI] in Adult Japanese Participants With Palmoplantar Pustulosis

Palmoplantar Pustulosis (PPP)

Japan
AbbVie

Completed

A Study in Healthy Japanese and Caucasian Subjects to Assess the Pharmacokinetics, Safety and Tolerability of Risankizumab

Healthy Volunteers

United States
AbbVie
Boehringer Ingelheim

Completed

BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment

Psoriasis
Huashan Hospital

Recruiting

The Effectiveness and Safety of Body Posture in Preventing Postoperative Recurrence for Chronic Subdural Hematoma

Recurrence | Chronic Subdural Hematoma

China
University Hospital, Ghent

Completed

Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis) (Koebner)

Vitiligo

Belgium
Forest Laboratories
AstraZeneca

Completed

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP)

Infections | Community Acquired Pneumonia

Spain, United States, Argentina, Bulgaria, Georgia, Greece, Hungary, Poland, Ukraine
AbbVie

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABBV-257 in Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

Germany
AbbVie

Completed

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis

Pancreatic Cancer

United States, Australia, Israel, Korea, Republic of, Puerto Rico, Spain
AbbVie

Terminated

A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer

Colorectal Cancer

United States
AbbVie

Recruiting

A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2)

Hepatocellular Carcinoma

United States, Taiwan, Spain, France
AbbVie

Completed

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

Crohn's Disease

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Ireland, Israel, Italy, Korea, Republic... and more
Genmab
AbbVie

Recruiting

Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

Non-hodgkin Lymphoma

United States, Australia, France, Israel, Korea, Republic of, Spain, Taiwan, Japan, Italy, Belgium, Germany, Canada, Turkey, Czechia
Calico Life Sciences LLC
AbbVie

Active, not recruiting

A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis | ALS

United States, Canada
AbbVie

Active, not recruiting

A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

United States, Australia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Taiwan
AbbVie

Recruiting

Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-1)

Hepatocellular Carcinoma

United States, Japan, Taiwan, Korea, Republic of, Spain, France, Italy
AbbVie

Completed

ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors

Advanced Solid Tumors | Squamous Cell Carcinoma of the Head and Neck | Undifferentiated Pleomorphic Sarcoma | Carcinoma of the Breast

United States, France, Spain
AbbVie

Withdrawn

An Efficacy and Safety Study of Injectable Ravagalimab to Assess Change in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) in Adult Participants With Moderately to Severely Active Primary Sjogren's Syndrome (pSS)

Sjogren's Syndrome (SS)

Netherlands
AbbVie

Completed

A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Psoriasis

Japan
AbbVie

Recruiting

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Budigalimab

Non-Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma

United States, Japan, Israel, Korea, Republic of
AbbVie

Completed

Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis

Psoriasis

United States, Canada, France, Germany, Italy, Netherlands, Poland, Spain, United Kingdom

3

Subscribe